FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and represents a method for editing the target RNA. RNA is edited using oligonucleotide constructs containing (i) a targeting site specific to the target nucleotide sequence to be edited; and (ii) a recruiting portion capable of binding and recruiting a structure which edits nucleic acid naturally present in the cell.
EFFECT: nucleic acid editing structure, for example, ADAR, is retargeted to a target site by a targeting portion, thereby initiating editing of the specified nucleotide residues within the target RNA region corresponding to the targeting site.
27 cl, 7 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENE EDITING USING MODIFIED CLOSED-END DNA (ceDNA) | 2018 |
|
RU2811724C2 |
| THERAPEUTIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | 2015 |
|
RU2711147C2 |
| METHODS AND PRODUCTS FOR EXPRESSION OF PROTEINS IN CELLS | 2013 |
|
RU2711249C2 |
| RNA-GUIDED HUMAN GENOME ENGINEERING | 2013 |
|
RU2766685C2 |
| CRISPR-CAS SYSTEM COMPONENTS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2701662C2 |
| NUCLEASE-MEDIATED DNA ASSEMBLY | 2015 |
|
RU2707911C2 |
| OLIGONUCLEOTIDES FOR MAKING CHANGE IN SEQUENCE OF TARGET RNA MOLECULE PRESENT IN LIVING CELL | 2013 |
|
RU2663110C2 |
| TREATMENT OF DISEASES CONNECTED WITH SITE-1 MEMBRANE-IMPACTED PEPTIDASE OF TRANSCRIPTION FACTORS (MBTPS1), BY INHIBITING NATURAL ANTISENSE TRANSCRIPT TO MBTPS1 | 2010 |
|
RU2639550C2 |
| METHOD FOR EDITING THE GJB2 GENE TO CORRECT THE PATHOGENIC VARIANT OF c.del35G IN HUMAN CELLS CULTURED IN VITRO | 2021 |
|
RU2780677C1 |
| RNA-GUIDED ENGINEERING OF HUMAN GENOME | 2013 |
|
RU2699523C2 |
